The International Federation of Clinical Chemistry – Scientific Division (IFCC-SD) and the Greek Society of Clinical Chemistry – Clinical Biochemistry Organize a Joint Hybrid Symposium

Place: Herakleion – Creta Greece
Date: 2 October 2022
Time: 11:00 am -13:00 pm

Symposium Title
Medical Test Performance should keep pace with Evolution in Science and Clinical Guidelines: state of play and challenges for CardioVascular Disease tests in this era of Precision Medicine.

Moderators
Dr Christa Cobbaert (IFCC-SD) – Dr Konstantinos Makris (IFCC-SD and GSCC-CB)

<table>
<thead>
<tr>
<th>Speech title</th>
<th>speaker</th>
<th>email</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The role of conventional biomarkers on the long-term CVD risk estimation. New approaches on the analytical performance standardization and the traceability of the measurements</td>
<td>Yannis Sdranis</td>
<td><a href="mailto:ysdranis@hotmail.com">ysdranis@hotmail.com</a></td>
</tr>
<tr>
<td>2. Current ESC/EAS clinical guideline demands accurate and fit-for-purpose apolipoprotein biomarkers beyond serum lipids</td>
<td>Christa Cobbaert</td>
<td><a href="mailto:C.M.Cobbaert@lumc.nl">C.M.Cobbaert@lumc.nl</a></td>
</tr>
<tr>
<td>3. Judging the clinical suitability of analytical performance of cardiac troponin assays</td>
<td>Mauro Panteghini</td>
<td><a href="mailto:mauro.panteghini@unimi.it">mauro.panteghini@unimi.it</a></td>
</tr>
<tr>
<td>4. Progress on Standardisation of brain natriuretic peptides</td>
<td>Lusie Luckau</td>
<td><a href="mailto:luise.luckau@lgcgroup.com">luise.luckau@lgcgroup.com</a></td>
</tr>
</tbody>
</table>

The objectives of the symposium could be summarized so as to give answers to the following questions:

1. What clinical performance do clinicians expect from cardiovascular disease (CVD) tests (described in clinical guidelines)?
2. What does this imply for the analytical performance requirements (among them bias, imprecision, selectivity at the low end, interference budget, MU) of these CVD tests?
3. Are the interdependent analytical and clinical performance requirements sufficiently aligned and do they guarantee that CVD tests are clinically fit-for purpose? Or do we need better tests?
4. What are the activities from relevant IFCC WG or C (each speaker participates) now and future goals?

Speakers Photos and affiliations

Prof. Christa M. COBBAERT

IFCC-SD vice chair
Laboratory Specialist and Head of the Department of Clinical Chemistry and Laboratory Medicine
Leiden University Medical Centre
Postbus 9600 Postzone E2-P
2300 RC Leiden - The Netherlands

c.m.cobbaert@lumc.nl

Dr. Konstantinos Makris

Member of IFCC Scientific Division Executive Committee
Clinical Biochemist
Director of Clinical Biochemistry Department
KAT General Hospital
2 Nikis street, 14561, Kifissia
Athens, Greece

kostas.makris@kat-hosp.gr

Prof. Mauro Panteghini

Research Centre for Metrological Traceability in Laboratory Medicine (CIRME),
University of Milan,
Milan, Italy
mauro.panteghini@unimi.it

Dr. Yannis Sdranis
Clinical Biochemist.
Department of Biochemistry,
University General Hospital of Ioannina,
Ioannina, Greece
ysdranis@hotmail.com

Dr. Luise Luckau
Lead Researcher Protein Mass Spectrometry - Organic Analysis
National Measurement Laboratory
LGC, Queens Road, Teddington,
Middlesex, TW11 0LY UK
luise.luckau@lgcgroup.com